Product Details
Only PreserVision® Eye Vitamin AREDS 2 Formula contains the exact levels of six nutrients recommended by the National Eye Institute to help reduce the risk of progression in people with moderate to advanced Age-related Macular Degeneration (AMD).*
PreserVision Eye Vitamin AREDS 2 Formula builds on the original, clinically proven PreserVision AREDS formula, with lutein and zeaxanthin replacing beta-carotene based on the National Eye Institute’s Age-Related Eye Disease Study 2 (AREDS2).
- Smaller pill vs. original PreserVision AREDS 2 Soft Gel
- Patented formula not available in any other brand
- #1 doctor recommended brand1
- 2 soft gels (MiniGels) per day
What The Results Mean For You?
The AREDS2 clinical study conducted by the National Eye Institute of the National Institutes of Health, completed in 2013, included thousands of patients. PreserVision AREDS 2 formula contains the updated formula now recommended by the National Eye Institute to help reduce the risk of moderate to advanced AMD progression.
Can a daily multivitamin alone provide the same benefits as an AREDS2 formulation?
No. The vitamins and minerals tested in the AREDS and AREDS2 studies were provided in much higher doses than what is found in typical multivitamins. Also, it is important to remember that most of the study participants took a daily multivitamin in addition to an AREDS 2 formula supplement.4
Improtant Thing To Know
Age-related Macular Degeneration (AMD)Â is a disease associated with aging that may gradually destroy sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving. AMD affects the macula, the part of the eye that allows you to see fine detail, but causes no pain.
In some cases, AMD advances so slowly that people notice little change in their vision. In others, the disease progresses faster and may lead to a loss of vision in both eyes. AMD is a leading cause of blindness in Americans 60 years of age and older.6
Reviews
There are no reviews yet.